Publications
266
Citations
9,547
Est. group size
~17
Recurring co-author estimate
Active years
55
Publishing since 1972
Typically publishes in teams of ~6 · 29% small-team papers (≤3 authors) · across 28 venues
- Daptomycin dosing in clinical practice-fixed dose vs. weight-related dose: the role of therapeutic drug monitoring
Academia Drug Development and Pharmacotherapy · 2026
- Toward the Future: A Race‐Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug Dosing
Clinical Pharmacology & Therapeutics · 2026
- Correction: Moreal et al. Daptomycin dosing in clinical practice-fixed dose vs. weight-related dose: the role of therapeutic drug monitoring. Acad. Drug. 2026, 2, 8303
Academia Drug Development and Pharmacotherapy · 2026
- Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?
Antimicrobial Agents and Chemotherapy · 2025
- Precision Daptomycin Dosing: Comparison of 3‐, 2‐, 1‐, and 0‐Concentration Sample Strategies
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2025
- Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion
Antimicrobial Agents and Chemotherapy · 2025
- Evaluation of High-dose Daptomycin in Children With Methicillin-resistant Staphylococcus aureus Bacteremia: A Case Series
The Pediatric Infectious Disease Journal · 2025
- 610 | RELATIVE EFFICACY OF VENETOCLAX PLUS IBRUTINIB VERSUS BRUTON TYROSINE KINASE INHIBITOR MONOTHERAPY AND CHEMOIMMUNOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Hematological Oncology · 2025
- Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Partial‐ and Full‐Thickness Skin Burns
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2025
- Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing <i>Enterobacterales</i>
Antimicrobial Agents and Chemotherapy · 2024
- An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing <i>Enterobacterales</i> and preventing resistance development in critically ill patients
Journal of Antimicrobial Chemotherapy · 2024
- Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in <i>Staphylococcus aureus</i> infections
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
- Hepatocellular carcinoma in clinical morquio syndrome - challenges for surgeons - a case report
HPB · 2024
- AB0069 MEASUREMENT OF IL-33/ST2 AXIS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND ITS ASSOCIATION WITH OTHER CYTOKINES IN SW982 AND U937 CELL LINES
Annals of the Rheumatic Diseases · 2023
- 2554. What’s Weight Got to Do with It? Prospective Pharmacokinetic/Pharmacodynamic Evaluation of Fixed-Dose Daptomycin
Open Forum Infectious Diseases · 2023
- Antimicrobial Agents and Chemotherapy×19
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy×14
- Clinical Infectious Diseases×7
- Journal of Antimicrobial Chemotherapy×7
- Open Forum Infectious Diseases×7
- Ryan L. Crass
Medicine · University of Michigan
- Michael Kays
Medicine · Purdue University West Lafayette
- Bruce A. Mueller
Medicine · University of Michigan
- Sharon M. Erdman
Medicine · Purdue University West Lafayette
- Kevin M. Sowinski
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile